Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic.
暂无分享,去创建一个
M. Malý | S. Snopková | D. Sedláček | M. Vraná | H. Rozsypal | L. Machala | J. Kapla | M. Staňková | D. Jilich | A. Zjevíková | Z. Jerhotová | J. Kolčáková | L. Olbrechtová
[1] Yao Ju,et al. HLA-B~*5701 screening for hypersensitivity to abacavir , 2011 .
[2] A. Urbańska,et al. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV‐infected patients , 2010, HIV medicine.
[3] C. Orkin,et al. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B*5701 in HIV‐1‐infected UK subjects , 2010, HIV medicine.
[4] H. Faruki,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.
[5] S. Mallal,et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] M. Foisy,et al. Abacavir Hypersensitivity Reaction: an Update , 2008, The Annals of pharmacotherapy.
[7] Hsin-Yun Sun,et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. , 2007, The Journal of antimicrobial chemotherapy.
[8] I. James,et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients , 2007, AIDS.
[9] S. Mallal,et al. Clinical and immunogenetic correlates of abacavir hypersensitivity , 2005, AIDS.
[10] E. Ivašková,et al. HLA-A, -B, -Cw, -DPB1, -DQA1, -DQB1 and -DRB1 allele frequencies in a population from the Czech Republic , 2004 .
[11] M. Pirmohamed,et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.
[12] Clive E. Bowman,et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.
[13] O. Naderer,et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.
[14] C. Moore,et al. HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2022 .